Enhancing tumor antigenicity, lymphocyte priming and migration, cancer cell killing and the reduction of the immunosuppressive tumor microenvironment (TME) represent promising strategies to boost antitumor immunity and to implement the efficacy of a PD-1/PD-L1 blockade [12,13]. Here, CD274 is linked to cancer.